Total Payments
$14,336
2024 Payments
$142.74
Companies
54
Transactions
260
Medicare Patients
2,429
Medicare Billing
$232,147
Payment Breakdown by Category
Research$10,170 (70.9%)
Food & Beverage$4,054 (28.3%)
Education$112.09 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10,170 | 5 | 70.9% |
| Food and Beverage | $4,054 | 253 | 28.3% |
| Education | $112.09 | 2 | 0.8% |
Payments by Type
Research
$10,170
5 transactions
General
$4,166
255 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $7,125 | 8 | $0 (2023) |
| Eli Lilly and Company | $3,132 | 3 | $0 (2023) |
| Novo Nordisk Inc | $561.10 | 38 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $437.90 | 31 | $0 (2024) |
| Lilly USA, LLC | $272.84 | 13 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $252.43 | 16 | $0 (2019) |
| ABBVIE INC. | $251.23 | 19 | $0 (2023) |
| GlaxoSmithKline, LLC. | $205.95 | 12 | $0 (2023) |
| Allergan, Inc. | $158.62 | 11 | $0 (2020) |
| Astellas Pharma US Inc | $157.49 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $142.74 | 7 | AstraZeneca Pharmaceuticals LP ($32.68) |
| 2023 | $8,227 | 47 | PFIZER INC. ($7,038) |
| 2022 | $1,017 | 36 | Eli Lilly and Company ($446.00) |
| 2021 | $2,667 | 14 | Eli Lilly and Company ($2,438) |
| 2020 | $72.71 | 5 | Novo Nordisk Inc ($17.37) |
| 2019 | $463.65 | 30 | AstraZeneca Pharmaceuticals LP ($139.03) |
| 2018 | $827.92 | 55 | Boehringer Ingelheim Pharmaceuticals, Inc. ($111.02) |
| 2017 | $917.72 | 66 | Novo Nordisk Inc ($330.68) |
All Payment Transactions
260 individual payment records from CMS Open Payments — Page 2 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/22/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Diabetes | ||||||
| 08/15/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: NEUROSCIENCE | ||||||
| 08/08/2023 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: Endocrinology | ||||||
| 08/03/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Respiratory | ||||||
| 07/20/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.76 | General |
| Category: Cardio-renal | ||||||
| 07/11/2023 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $26.50 | General |
| 06/30/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: RESPIRATORY | ||||||
| 06/22/2023 | NESTLE HEALTHCARE NUTRITION INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $20.24 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 06/21/2023 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Education | In-kind items and services | $17.10 | General |
| Category: NEPHROLOGY | ||||||
| 06/15/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Bone Health | ||||||
| 05/30/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $13.28 | General |
| Category: Diabetes | ||||||
| 05/25/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $86.43 | General |
| Category: Diabetes | ||||||
| 05/23/2023 | NESTLE HEALTHCARE NUTRITION INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 05/09/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $16.41 | General |
| 05/04/2023 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Diabetes | ||||||
| 04/11/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: Cardio-renal | ||||||
| 03/28/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Nephrology | ||||||
| 03/16/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: NEPHROLOGY | ||||||
| 03/14/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: NEUROSCIENCE | ||||||
| 03/07/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: RESPIRATORY | ||||||
| 03/01/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: Cardio-renal | ||||||
| 02/23/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Obesity | ||||||
| 02/07/2023 | NESTLE HEALTHCARE NUTRITION INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $247.95 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | ||||||
| 01/31/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $7,038 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $2,884 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $247.95 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 349 | 545 | $97,955 | $39,711 |
| 2022 | 13 | 582 | 895 | $152,683 | $64,649 |
| 2021 | 13 | 709 | 1,044 | $157,378 | $66,389 |
| 2020 | 16 | 789 | 1,150 | $170,324 | $61,398 |
Total Patients
2,429
Total Services
3,634
Medicare Billing
$232,147
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 106 | 234 | $48,204 | $16,831 | 34.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 67 | 67 | $14,606 | $8,352 | 57.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 60 | 123 | $17,220 | $7,128 | 41.4% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 26 | 28 | $12,516 | $4,934 | 39.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 14 | $2,842 | $1,226 | 43.1% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 61 | 61 | $2,135 | $1,089 | 51.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 18 | 18 | $432.00 | $151.20 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 124 | 302 | $62,212 | $22,895 | 36.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 94 | 94 | $20,492 | $11,936 | 58.2% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2022 | 34 | 39 | $17,433 | $7,703 | 44.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 65 | 122 | $17,080 | $7,220 | 42.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 23 | 79 | $10,744 | $4,305 | 40.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 18 | $4,968 | $2,271 | 45.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 23 | $5,980 | $2,167 | 36.2% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 13 | 14 | $4,438 | $1,989 | 44.8% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 93 | 93 | $3,255 | $1,659 | 51.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 12 | $2,436 | $963.85 | 39.6% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2022 | 23 | 23 | $1,725 | $727.49 | 42.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 24 | 24 | $672.00 | $658.56 | 98.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 43 | 52 | $1,248 | $153.54 | 12.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 149 | 351 | $72,306 | $26,499 | 36.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 114 | 114 | $24,852 | $14,460 | 58.2% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 27 | 36 | $16,092 | $7,531 | 46.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 74 | 119 | $16,660 | $6,903 | 41.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 22 | 69 | $9,384 | $3,769 | 40.2% |
About Dr. Bharathi Pulla, M.D
Dr. Bharathi Pulla, M.D is a Geriatric Medicine healthcare provider based in Kenosha, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/05/2007. The National Provider Identifier (NPI) number assigned to this provider is 1962559302.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bharathi Pulla, M.D has received a total of $14,336 in payments from pharmaceutical and medical device companies, with $142.74 received in 2024. These payments were reported across 260 transactions from 54 companies. The most common payment nature is "" ($10,170).
As a Medicare-enrolled provider, Pulla has provided services to 2,429 Medicare beneficiaries, totaling 3,634 services with total Medicare billing of $232,147. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Medicine
- Other Specialties Adolescent Medicine
- Location Kenosha, WI
- Active Since 01/05/2007
- Last Updated 06/28/2023
- Taxonomy Code 207QG0300X
- Entity Type Individual
- NPI Number 1962559302
Products in Payments
- NURTEC ODT (Drug) $7,060
- FARXIGA (Drug) $254.56
- JARDIANCE (Drug) $226.93
- Saxenda (Drug) $187.53
- VRAYLAR (Drug) $171.21
- Kerendia (Drug) $154.98
- Victoza (Drug) $134.49
- ZENPEP (Drug) $119.41
- TRELEGY ELLIPTA (Drug) $112.42
- TRULICITY (Drug) $108.24
- LINZESS (Drug) $108.03
- MOUNJARO (Drug) $102.93
- JANUVIA (Drug) $100.44
- ENTRESTO (Drug) $97.26
- BREO (Drug) $93.53
- Rybelsus (Drug) $72.50
- JYNARQUE (Drug) $70.66
- BREZTRI (Drug) $69.15
- NOCDURNA (Drug) $68.71
- LOKELMA (Drug) $65.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.